- Home
- » Tags
- » Carfilzomib
Top View
- DRUG NAME: Carfilzomib
- Current Treatment Options for WM
- Bc Cancer Chemotherapy Preparation and Stability
- Proccode NDC Description Facility Non-Facility Effective Date
- Prophylaxis Guidelines for the Adult Hematology Patient
- KYPROLIS (Carfilzomib) for Injection Is an Antineoplastic Agent Available for Intravenous Use Only
- 2019 Table of Drugs
- Carfilzomib (Kyprolis)
- Replacement of Bortezomib with Carfilzomib for Multiple Myeloma
- Brand Generic Guide
- Phase 1B Trial of Proteasome Inhibitor Carfilzomib with Irinotecan in Lung
- A Pooled Analysis of Two Studies
- Therapeutic Role of Arsenic Trioxide in Cancer Protection Archana Chaudhary and Rizwanul Haque*
- Carfilzomib Does Not Improve Outcomes in Newly Diagnosed Myeloma Compared to Bortezomib
- The Side Effect Profile of Carfilzomib: from Clinical Trials to Clinical Practice
- 202714Orig1s000
- Downloading Or Printing (E.G
- Kyprolis, INN-Carfilzomib
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Kyprolis® (Carfilzomib)
- UMYCARDEX Protocol
- Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan
- Response Rate to the Treatment of Waldenström Macroglobulinemia: a Meta-Analysis of the Results of Clinical Trials
- Kyprolis® (Carfilzomib)
- International Journal of Hematology and Therapy Cladribine in The
- Waldenstrom Macroglobulinemia
- Carfilzomib Or Bortezomib in Combination With
- Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity Of
- Medical Drug Prior Authorization List/External Posting Effective August 2021 Page 1 Last Updated 8/4/2021
- (12) Patent Application Publication (10) Pub. No.: US 2011/0009353 A1 Chen-Kiang Et Al
- Carfilzomib in Combination with Bortezomib Enhances Apoptotic
- Combination of the Peptide Epoxyketone Proteasome Inhibitor
- The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
- Carfilzomib, Cyclophosphamide and Dexamethasone (KCD)
- Investigator-Initiated Trial PROTOCOL INFORMATION Study Title
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- CYCLOPHOSPHAMIDE / CARFILZOMIB / DEXAMETHASONE (Cycardex)
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- High-Dose Weekly Carfilzomib, Cyclophosphamide, and Dexamethasone in the Treatment of Patients with Relapsed and Refractory Mult
- Kyprolis (Carfilzomib) Is Supplied As
- A Clinical Perspective on Plasma Cell Leukemia; Current Status and Future Directions Sherilyn A
- Carfilzomib (Kyprolis®)
- An Open-Label, Single-Arm, Phase 2 Study of PR-171 in Patients With
- Carfilzomib Promotes the Unfolded Protein Response and Apoptosis In
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Disease(S) Brand Name Drug Name Drug Company Phone Number Website Calaspargase No Financial Assistance Offered at This Asparlas Servier Pegol-Mknl Time
- Do Not Tube List
- Full Text (PDF)
- HOPA News Volume 9, Issue 3
- All ETCTN Trials
- Antineoplastic Drug Administration: Vesicant and Irritant Agents (Oncology) - CE
- A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- Hazardous Drug List
- A Phase II, Single-Arm, Prospective Study of Bendamustine Plus
- Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Treatment Regimens
- Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies EDVIN DESTANOVIC, JOACHIM BOOS and CLAUDIA LANVERS-KAMINSKY